Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives $15.00 Consensus Target Price from Analysts

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) have been given an average rating of “Buy” by the eight research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $15.00.

A number of research analysts recently weighed in on ACHV shares. Wall Street Zen cut shares of Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Achieve Life Sciences in a report on Wednesday, August 12th. Morgan Stanley assumed coverage on shares of Achieve Life Sciences in a research report on Thursday, August 13th. They issued an “overweight” rating and a $13.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Wednesday, August 19th. Finally, UBS Group reaffirmed a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 12th.

Insider Buying and Selling

In related news, Director Richard Stewart sold 20,626 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total transaction of $175,114.74. Following the completion of the transaction, the director directly owned 208,249 shares of the company’s stock, valued at $1,768,034.01. The trade was a 9.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Achieve Life Sciences

A number of hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new position in shares of Achieve Life Sciences during the second quarter worth about $49,000. Magnolia Capital Advisors LLC purchased a new stake in shares of Achieve Life Sciences during the second quarter worth approximately $99,000. Jefferies Financial Group Inc. acquired a new stake in Achieve Life Sciences in the fourth quarter valued at approximately $84,000. The Manufacturers Life Insurance Company acquired a new stake in Achieve Life Sciences in the second quarter valued at approximately $135,000. Finally, Keating Financial Advisory Services Inc. purchased a new position in Achieve Life Sciences in the second quarter worth approximately $163,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Price Performance

ACHV stock opened at $7.83 on Monday. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $805.71 million, a PE ratio of -5.05 and a beta of 2.25. Achieve Life Sciences has a 12-month low of $2.62 and a 12-month high of $8.64. The business’s fifty day moving average price is $7.28 and its 200 day moving average price is $5.64.

Achieve Life Sciences (NASDAQ:ACHV) last announced its earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64). On average, sell-side analysts anticipate that Achieve Life Sciences will post -0.91 EPS for the current year.

About Achieve Life Sciences

Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company focused on developing and commercializing cytisinicline, an investigational therapy designed to help adults stop smoking and address nicotine dependence. The company is listed on the Nasdaq Capital Market under the symbol ACHV.

Cytisinicline is a plant-derived small molecule that acts on neuronal nicotinic acetylcholine receptors involved in nicotine addiction. Achieve is evaluating the therapy in clinical studies for smoking cessation and potential support for quitting other forms of nicotine use.